Abstract
Purpose :
We conducted a multicenter retrospective study to investigate potential risk factors for recurrence in patients with central serous chorioretinopathy (CSC).
Methods :
The study was performed at 8 medical institutions from 2008 to 2020 in Japan on patients who had experienced an active episode of CSC. Exclusion criteria included indications of choroidal neovascularization (CNV), polypoidal choroidal vasculopathy (PCV), and any other ophthalmology related disease. Demographic data and medical history, including age, gender, best corrected visual acuity (BCVA), spherical equivalent, fellow-eye status, history of corticosteroid use or smoking, frequency of recurrence, and treatment choices were noted. In addition, significant differences in central retinal thickness, subfoveal choroidal thickness, chronic manifestation, numbers of leakage points, leakage intensity (intense/subtle), leakage sites in the inner or outer foveal avascular zone (FAZ), and choroidal hyperpermeability were analyzed as between recurrence and non-recurrence groups.
Results :
Six hundred forty (640) of 699 patients with CSC (700 eyes; 478 males, 162 females; mean age 52.7 ± 12.1 years) were enrolled by application of the exclusion and inclusion criteria. Among these 640 patients, 323 (50.5%) presented ≥1 recurrence. The average time to the first recurrence was 35.8 ± 45.8 months (range1-360 months), and the mean frequency of recurrence was 1.16 ± 0.50.
There were no statistically significant differences in age or gender distribution, smoking history, BCVA at baseline and final visit, spherical equivalent, central retinal thickness, leakage site, or subfoveal choroidal thickness between the recurrence and non-recurrence groups. Nevertheless, history of corticosteroid use (P = 0.0003), bilateral CSC (P<0.0001), non-therapy (P<0.0001), chronic performance on FAF (P＜0.0001)，≥2 leakage points (P＝0.0014), and subtle fluorescein leakage（P＝0.0309）were significantly related to an increased risk of recurrence.
Conclusions :
Knowledge of these data and multiple risk factors serving as predictors might aid in early detection or intensive treatment for patients with CSC at high risk of recurrence.
This is a 2021 ARVO Annual Meeting abstract.